Hereditary transthyretin amyloidosis from a Scandinavian perspective

. Suhr OB, Svendsen IH, Andersson R, Danielsson Å, Holmgren G, Ranløv PJ (Umeå University Hospital, Umeå, Sweden; Rigshospitalet, København Ø, Denmark; Örnsköldsviks Hospital, Örnsköldsvik, Sweden; and Hørsholm Hospital, Hørsholm, Denmark). Hereditary transthyretin amyloidosis from a Scandinavian pe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 2003-09, Vol.254 (3), p.225-235
Main Authors: Suhr, O. B., Svendsen, I. Hastrup, Andersson, R., Danielsson, Å., Holmgren, G., Ranløv, P. J.
Format: Article
Language:English
Subjects:
Age of Onset
Amyloid Neuropathies - etiology
Amyloidosis
amyloidosis (hereditary)
Amyloidosis, Familial - diagnosis
Amyloidosis, Familial - genetics
Amyloidosis, Familial - therapy
Biological and medical sciences
Gastrointestinal Diseases - etiology
Genetic Counseling
Heart Diseases - etiology
Heart Transplantation
Humans
inborn errors of metabolism
Kidney Diseases - etiology
Liver Transplantation
Medical sciences
Metabolic diseases
Mutation - genetics
Other metabolic disorders
Postoperative Complications - etiology
Prealbumin - genetics
Scandinavian and Nordic Countries
transplantation (liver and heart)
transthyretin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:. Suhr OB, Svendsen IH, Andersson R, Danielsson Å, Holmgren G, Ranløv PJ (Umeå University Hospital, Umeå, Sweden; Rigshospitalet, København Ø, Denmark; Örnsköldsviks Hospital, Örnsköldsvik, Sweden; and Hørsholm Hospital, Hørsholm, Denmark). Hereditary transthyretin amyloidosis from a Scandinavian perspective (Review). J Intern Med 2003; 254: 225–235. Hereditary transthyretin (TTR) amyloidosis is a rare often fatal form of systemic amyloidosis, that until recently was considered intractable, with the patients dying from the disease 5–15 years after onset. The phenotype of the disease varies according to the type of mutation, but generally the heart and/or the nervous system is affected. Liver and in some cases heart transplantation has now been shown to stop the progress of the disease, but the outcome depends on the patients’ status at the time of operation, as no substantial improvement of the patients’ symptoms has been noted after the procedure. Thus an early diagnosis is of importance for the outcome. In the following, we summarize our knowledge of the amyloidogenic TTR mutations found in the Scandinavian countries, their symptoms, how to settle the diagnosis and the outcome of transplantation. Besides, the problems arising from our capability to genetically test asymptomatic members of affected families for the trait will be discussed.
ISSN:0954-6820
1365-2796
DOI:10.1046/j.1365-2796.2003.01173.x